JAHA:心房颤动患者心理健康状况与直接口服抗凝剂不依从性的关系

2022-03-02 MedSci原创 MedSci原创

心理健康状况与直接口服抗凝剂使用的不依从性相关。

心理健康状况与心房颤动患者的不良预后相关。然而,对于心理健康状况与心房颤动患者口服抗凝治疗治疗的不依从性之间关系尚未明确。

近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员旨在基于全国队列评估心理健康状况对房颤患者持续使用直接口服抗凝剂的影响。

基于全国注册的芬兰房颤抗凝治疗(FinACAF)队列,研究人员纳入了2011年至2018年期间开始直接口服抗凝剂治疗和永久口服抗凝剂(男性CHA2DS2-VASc评分>1和女性>2)的67503名心房颤动患者。感兴趣的心理健康状况包括抑郁症、双相情感障碍、焦虑症、精神分裂症和任何心理健康状况的复合结局。该研究的主要结局是直接口服抗凝剂使用的不依从性程度,定义为开始药物治疗后前120天内没有购买直接口服抗凝剂。

患者的平均年龄为75.3±8.9岁,53.6%为女性,任何心理健康状况的患病率为17.8%。直接口服抗凝剂开始治疗1年后的依从性在没有心理健康状况的患者中为79.3%,在伴有任何心理健康状况的患者中为77.2%,在2年后分别为64.4%和60.6%(P<0.001)。

在所有心理健康状况类别中,研究人员观察到直接口服抗凝剂较高的不依从性发生率:调整后的亚组分布风险比,对于任何心理健康状况为1.16(95%CI为1.11-1.21),对于抑郁症为1.32(95%CI为1.22-1.42),对于双相情感障碍为1.44(95%CI为1.15-1.80),对于焦虑症为1.25(95%CI为1.11-1.41),对于精神分裂症为1.30(95%CI为1.02-1.64)。然而,仅患有焦虑症而没有其他心理健康状况的患者没有更高的不依从性风险。

由此可见,心理健康状况与直接口服抗凝剂使用的不依从性相关。

原始出处:

Konsta Teppo.et al.Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study.JAHA.2022.https://www.ahajournals.org/doi/10.1161/JAHA.121.024119

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1268775, encodeId=c9cc1268e7586, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309795, encodeId=641b1309e95a9, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319365, encodeId=6624131936562, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441168, encodeId=7fc914411684c, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511050, encodeId=fb3c151105050, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626983, encodeId=0c0b16269838b, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=)]
    2022-03-03 zhaohui6731
  2. [GetPortalCommentsPageByObjectIdResponse(id=1268775, encodeId=c9cc1268e7586, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309795, encodeId=641b1309e95a9, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319365, encodeId=6624131936562, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441168, encodeId=7fc914411684c, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511050, encodeId=fb3c151105050, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626983, encodeId=0c0b16269838b, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1268775, encodeId=c9cc1268e7586, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309795, encodeId=641b1309e95a9, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319365, encodeId=6624131936562, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441168, encodeId=7fc914411684c, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511050, encodeId=fb3c151105050, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626983, encodeId=0c0b16269838b, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=)]
    2022-03-03 fyxzlh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1268775, encodeId=c9cc1268e7586, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309795, encodeId=641b1309e95a9, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319365, encodeId=6624131936562, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441168, encodeId=7fc914411684c, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511050, encodeId=fb3c151105050, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626983, encodeId=0c0b16269838b, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1268775, encodeId=c9cc1268e7586, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309795, encodeId=641b1309e95a9, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319365, encodeId=6624131936562, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441168, encodeId=7fc914411684c, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511050, encodeId=fb3c151105050, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626983, encodeId=0c0b16269838b, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1268775, encodeId=c9cc1268e7586, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309795, encodeId=641b1309e95a9, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319365, encodeId=6624131936562, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441168, encodeId=7fc914411684c, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511050, encodeId=fb3c151105050, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626983, encodeId=0c0b16269838b, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Thu Mar 03 12:59:13 CST 2022, time=2022-03-03, status=1, ipAttribution=)]
    2022-03-03 sodoo

相关资讯

JAHA:颈围与心房颤动风险的关系

调整了传统的肥胖指标(如BMI和腰围)后,较大的颈围与心房颤动事件相关。

测一测,您的房颤发生风险有多高?

中国台湾房颤发生风险得分(Taiwan AF Score)

消化道疾病也能引起房颤?涨见识了!

心房颤动是一种常见的心律失常疾病,是由于肺静脉内的异常电活动引起的,其常见的危险因素包括酗酒、甲状腺功能亢进、二尖瓣狭窄、高血压、糖尿病和冠状动脉疾病等。 但目前有一个很少见的危险因素是食管裂孔疝,突

Nature子刊:春节还在喝酒吗?节假日过度饮酒或会导致房颤风险激增!

节假日急性酒精摄入与不连续的房颤发作以及新发房颤的高风险有关。

Eur Heart J:无症状脑梗死对心房颤动患者认知功能的影响

在当代AF患者队列中,5.5%的MRI检查个体显示2年后出现新的脑梗死。这些梗塞个体大多数在临床上是无症状的,并且发生于抗凝患者中。临床上,明显和无症状的脑梗塞对认知能力下降存在类似的影响。